New drug combo targets Hard-to-Treat ovarian and endometrial cancers

NCT ID NCT05950464

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This early-phase trial is testing the safety and best dose of two drugs, M1774 and ZEN-3694, given together to patients with recurrent ovarian or endometrial cancer. The drugs work by blocking enzymes that cancer cells need to grow. The study aims to find a dose that is safe and potentially effective, especially in tumors with a specific genetic change (ARID1A loss).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

M1774 (ATR inhibitor) and ZEN-3694 (BET inhibitor)

What this could lead to

If successful, this could lead to a new treatment option for patients with recurrent ovarian or endometrial cancer that has stopped responding to standard therapies.

What could go wrong

This is an early phase 1 trial with only 65 participants, so safety and dosing are still being determined. The combination may cause side effects or not work as hoped.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial carcinoma endometrial clear cell adenocarcinoma endometrial endometrioid adenocarcinoma endometrium neoplasm ovarian carcinoma ovarian clear cell adenocarcinoma ovarian clear cell cancer ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Augusta University Medical Center

    SUSPENDED

    Augusta, Georgia, 30912, United States

  • Case Western Reserve University

    ACTIVE_NOT_RECRUITING

    Cleveland, Ohio, 44106, United States

  • Cleveland Clinic Foundation

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

    Contact Phone: •••-•••-••••

    Contact

  • NRG Oncology

    RECRUITING

    Philadelphia, Pennsylvania, 19103, United States

    Contact Email: •••••@•••••

    Contact

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Thomas Jefferson University Hospital

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Chicago Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Iowa/Holden Comprehensive Cancer Center

    RECRUITING

    Iowa City, Iowa, 52242, United States

    Contact

    Contact Phone: •••-•••-••••

  • University of New Mexico Cancer Center

    RECRUITING

    Albuquerque, New Mexico, 87106, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Oklahoma Health Sciences Center

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pennsylvania/Abramson Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Wayne State University/Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Women and Infants Hospital

    RECRUITING

    Providence, Rhode Island, 02905, United States

    Contact

    Contact Phone: •••-•••-••••